Hans J. Van Der Vliet

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 102 publications

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Lenalidomide boosts CD1d-Vδ2 bispecific antibody-engaged Vγ9Vδ2-T cell effector functions via CD28, Notch signaling and IL-2 release.

Journal: Journal for immunotherapy of cancer

Published: June 11, 2026

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

A trophoblast glycoprotein specific 5T4-Vδ2 bispecific T cell engager recruits Vγ9Vδ2-T cells for tumor-selective cytotoxicity across solid malignancies.

Journal: Clinical immunology (Orlando, Fla.)

Published: December 29, 2025

PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment.

PD-L1 directed bispecific Vδ2-T cell engager combines lysis of PD-L1 expressing tumor cells with PD-1 immune checkpoint inhibition and modulation of the tumor immune microenvironment.

Journal: Journal for immunotherapy of cancer

Published: October 08, 2025

An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy.

An organotypic human melanoma-in-skin model as an in vitro tool for testing Vγ9Vδ2-T cell-based immunotherapy.

Journal: Immuno-oncology technology

Published: September 02, 2024

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.

Vδ2 T-cell engagers bivalent for Vδ2-TCR binding provide anti-tumor immunity and support robust Vγ9Vδ2 T-cell expansion.

Journal: Frontiers in oncology

Published: July 31, 2024

Exploring the effects of exercise on immune cell function and tumour infiltration in patients with breast cancer receiving neoadjuvant chemotherapy - a feasibility trial.

Exploring the effects of exercise on immune cell function and tumour infiltration in patients with breast cancer receiving neoadjuvant chemotherapy - a feasibility trial.

Journal: Brain, behavior, & immunity - health

Published: July 17, 2024

Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort.

Reintroduction of palliative intent FOLFIRINOX chemotherapy in a real world pancreatic cancer cohort.

Journal: Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]

Published: June 21, 2024

Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.

Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.

Journal: Oncoimmunology

Published: June 13, 2024

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.

Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.

Journal: iScience

Published: May 09, 2024

Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells.

Vaccination with DC-SIGN-Targeting αGC Liposomes Leads to Tumor Control, Irrespective of Suboptimally Activated T-Cells.

Journal: Pharmaceutics

Published: March 19, 2024

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions.

Enhanced CD1d phosphatidylserine presentation using a single-domain antibody promotes immunomodulatory CD1d-TIM-3 interactions.

Journal: Journal for immunotherapy of cancer

Published: November 05, 2023

Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer.

Allogeneic NK cells induce monocyte-to-dendritic cell conversion, control tumor growth, and trigger a pro-inflammatory shift in patient-derived cultures of primary and metastatic colorectal cancer.

Journal: Journal for immunotherapy of cancer

Published: October 17, 2023

Showing 1-12 of 102

Last Updated: 09/26/2026